Cytisinicline: A New Quit-Smoking Pill Nears FDA Decision

For Maria, a 47-year-old who has smoked since she was a teenager, the math is brutally familiar. She has tried the patch, the gum, sheer willpower over a New Year, and a prescription she abandoned after a week of vivid dreams. Each attempt ended the same way, with a cigarette outside the back door and a quiet promise to try again. Millions of Americans know that loop intimately. Now, for the first time in roughly twenty years, a genuinely new prescription option for people like Maria is sitting on the desk of federal regulators, awaiting a verdict.

The drug is cytisinicline, an investigational pill from Achieve Life Sciences. The Food and Drug Administration has set a decision deadline, known as a PDUFA date, of around June 20, 2026. If it clears, cytisinicline would become the first new prescription smoking-cessation medication approved in the United States since varenicline, sold as Chantix, arrived in 2006.

How the Pill Works

Cytisinicline is not a laboratory novelty. It is a refined version of cytisine, a plant-derived alkaloid that has been used as a smoking aid in Central and Eastern Europe for decades. Chemically, it belongs to the same family of medicines as varenicline. It binds with high affinity to nicotinic acetylcholine receptors in the brain, the same receptors nicotine targets.

By acting as a partial agonist at those receptors, cytisinicline does two things at once. It blunts the cravings and withdrawal that make quitting so punishing, and it dulls the reward a smoker would normally get from lighting up. In practice, that means a cigarette delivers less of its usual hit, while the gnawing urge in between cigarettes gets quieter. The biology is the reason a plant compound used for generations is now being held to the rigor of modern clinical trials.

What the Trials Showed

Achieve built its application on two large Phase 3 studies, ORCA-2 and ORCA-3, which together enrolled more than 2,000 adult smokers. The numbers from ORCA-3, published in JAMA Internal Medicine and run in 792 U.S. adults, are the clearest snapshot of how the drug performs.

In the 12-week treatment arm, 30.3 percent of participants stayed abstinent from smoking during weeks 9 through 12, compared with 9.4 percent on placebo. That works out to more than four times the odds of quitting. A shorter six-week course produced a smaller but still significant benefit, with 14.8 percent abstinent versus 6 percent on placebo. Crucially, the effect did not evaporate the moment treatment stopped. In the 12-week group, roughly one in five participants remained continuously abstinent through week 24.

The safety picture has been reassuring, which matters enormously for a category haunted by side-effect concerns. In a year-long open-label safety study, 334 participants completed a full 12 months of treatment, and only about 2.5 percent reported nausea, with no new safety signals flagged. Dr. Nancy Rigotti of Harvard Medical School, a longtime tobacco-treatment researcher, put the stakes plainly, noting that more deaths each year in the United States are attributed to cigarette smoking than to any other preventable cause, and that a well-tolerated new option could help many smokers quit.

A Simple Course of Treatment

One of cytisinicline's selling points is how undramatic the regimen is. In the trials, participants took a 3-milligram tablet three times a day, paired with behavioral support, over either six or twelve weeks. There is no lengthy titration ramp and no requirement to set a quit date weeks in advance and white-knuckle it until the medicine kicks in.

That simplicity is not cosmetic. Smoking-cessation drugs only help if people actually finish the course, and complicated schedules are a quiet reason many quit attempts collapse. A short, tolerable, three-times-daily pill is the kind of design detail that can move real-world success rates, not just trial averages.

The Twenty-Year Drought

To understand why this decision is drawing attention, look at how little has changed on the pharmacy shelf. The last truly new prescription stop-smoking medicine was varenicline, approved in 2006. For two decades, smokers and their doctors have cycled through the same short menu: nicotine-replacement patches and gum, the antidepressant bupropion, and varenicline, which itself was temporarily disrupted by manufacturing recalls a few years ago.

The public-health need has not shrunk to match that stagnation. Roughly 29 million U.S. adults still smoke combustible cigarettes, and smoking is tied to more than 500,000 deaths in the country every year. Most smokers say they want to quit, and most who try will relapse. A new mechanism-backed option, with a long human track record behind its parent compound, would widen a toolkit that has been frozen for a generation.

The Vaping Frontier

Cytisinicline's ambitions do not stop at cigarettes. Achieve is also testing it for a problem that barely existed when varenicline launched: nicotine vaping. In the Phase 2 ORCA-V1 study of 160 adults who vaped but did not smoke, participants on cytisinicline were about 2.6 times more likely to quit vaping than those on placebo.

That signal was strong enough that the FDA granted the drug Breakthrough Therapy designation for e-cigarette cessation and later selected it for the agency's inaugural National Priority Voucher program, one of only a handful of therapies chosen. Regulators have also agreed on the design of a Phase 3 vaping trial, ORCA-V2, that could support a separate approval down the line. With teen and young-adult vaping a persistent worry, a medicine aimed squarely at that addiction would fill a gap no current prescription drug addresses.

What Approval Would Mean

Achieve's leadership has framed the moment in public-health terms. Chief Executive Rick Stewart has described nicotine dependence as an urgent need that demands action, while Chief Medical Officer Dr. Cindy Jacobs has pointed to the totality of the development program behind the application.

None of this is guaranteed. The FDA can approve, reject, or ask for more before its June deadline. But the trajectory is unusual for a field that has gone so long without fresh options. If cytisinicline crosses the line, the people who matter most are not in boardrooms or laboratories. They are the smokers standing outside back doors, telling themselves they will try again, and finally holding a new tool when they do.